Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
13.19
+0.41 (3.21%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Company Description
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Atrium Therapeutics, Inc.
| Country | United States |
| Founded | 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Kathleen Gallagher |
Contact Details
Address: 10578 Science Center Drive, Suite 125 San Diego, California 92121 United States | |
| Phone | 619 876 0700 |
| Website | atriumtherapeutics.com |
Stock Details
| Ticker Symbol | RNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002093101 |
| CUSIP Number | 04965N104 |
| ISIN Number | US04965N1046 |
Key Executives
| Name | Position |
|---|---|
| Kathleen P. Gallagher | President, Chief Executive Officer and Director |
| Brendan Winslow | Chief Financial Officer |
| Dr. Husam Younis | Chief Scientific Officer |
| Stephanie Kenney | Chief Corporate Affairs Officer |
| Dr. Steven George Hughes M.B.A., M.D. | Chief Medical Officer |
| Rocio Martin Hoyos | Chief Strategy Officer |